OBJECTIVEdThe aim of this study was to evaluate HbA 1c as an alternative criterion for impaired glucose tolerance (IGT) or type 1 diabetes (T1D) in high-risk subjects ,21 years of age.
levated HbA 1c has been proposed by the joint American Diabetes Association (ADA), International Diabetes Federation, and European Association for the Study of Diabetes International Expert Committee (IEC) as an alternative criterion for the diagnosis of diabetes (1) . HbA 1c reflects a 90-day moving average of blood glucose concentrations, weighted more heavily toward the last 30 days, and may be more stable in the presence of significant day-to-day glycemic variation (2) . The recommended thresholds are $5.7% for impaired glucose tolerance (IGT) and $6.5% for diagnosis of diabetes on two tests (1) . These thresholds were established based on research conducted in adults with type 2 diabetes (T2D) who demonstrated significant correlations with HbA 1c $6.5% and higher prevalence of retinopathy and nephropathy (1, 3) . While recent research has substantiated rising HbA 1c as a predictor of type 1 diabetes (T1D) in both young (age ,15 years) (4) and adult (median age .50 years) populations (5) , data demonstrating appropriate HbA 1c thresholds for diagnosing T1D are lacking.
In .50% of children (6) , diagnosis is made when characteristic symptoms (polyuria, polydipsia, and weight loss) are associated with elevated blood glucose. The most widely used screening test in children is random plasma glucose (RPG) with characteristic symptoms, diagnostic if $200 mg/dL (11.1 mmol/L) and confirmed in a laboratory. Asymptomatic cases are rare and usually picked up on screening of urine (glucosuria or ketonuria) or blood (hyperglycemia) or among subjects known to be positive for islet autoantibodies. In these cases, fasting plasma glucose (FPG) and a 2-h oral glucose tolerance test (OGTT) are recommended and diagnostic if abnormal on two separate days. It is in these individuals that HbA 1c has gained appeal as a potential diagnostic indicator that would preclude the need for fasting tests and provide diagnostic data (1) .
Although there are many proponents for including HbA 1c as an alternative criterion for diagnosing diabetes, full consensus has not yet been achieved (7) . Most studies evaluating HbA 1c against the gold standard of the OGTT were carried out in subjects at increased risk for T2D (7) . In contrast, few studies have assessed the sensitivity and specificity of HbA 1c in children and adolescents: the age-group with the highest incidence of T1D.
The purpose of this study was to determine the utility of HbA 1c as an alternative criterion in diagnosing IGT and T1D in high-risk subjects ,21 years of age.
RESEARCH DESIGN AND METHODSdThe population for this study was derived from four prospective studies: Diabetes Prevention Trial-Type 1 (DPT-1) (8), Type 1 Diabetes TrialNet Natural History (TrialNet) (9), The Environmental Determinants of Diabetes in the Young (TEDDY) (10) , and Trial to Reduce IDDM in the Genetically at Risk (TRIGR) (11) . All subjects ,21 years of age with an HbA 1c and OGTT drawn within 90 days of each other were eligible for the primary analysis. IGT and T1D were defined using the joint IEC criteria: OGTT 2-h plasma glucose (2-hPG) between 140 and 199 mg/dL (7.8 and 11.0 mmol/L) was classified as IGT, and FPG $126 mg/dL ($7.0 mmol/L) or OGTT 2-hPG $200 mg/dL ($11.1 mmol/L) was classified as T1D (1) . The primary objective was to assess how well HbA 1c performed in diagnosing T1D and IGT compared with the OGTT. To do this, the maximum HbA 1c collected within a 90-day window before or after the OGTT was used; the two measures were paired to assess the sensitivity and specificity. For those diagnosed with T1D or IGT, the diagnostic HbA 1c and OGTT pair was used, and for those without T1D/ IGT the maximum HbA 1c -OGTT pair across the follow-up period was used. Secondary analysis evaluated the subjects diagnosed with T1D who did not have an OGTT within the 90-day window in TEDDY and DPT-1 but had HbA 1c collected within 7 days for TEDDY and 90 days for DPT-1 of diagnosis based on symptoms, FPG, RPG, and/or asymptomatic hyperglycemia (i.e., the diagnostic HbA 1c was used). These subjects may have been clinically different but met the IEC criteria. The details for these four studies have previously been described (8, 9, 10, 11) . OGTT. DPT-1 and TrialNet evaluated OGTT samples using a photometric measurement of D-glucose absorbance using Modular P autoanalyzer (Roche Diagnostics, Indianapolis, Indiana). TRIGR evaluated OGTT samples at each of the 77 sites using one of the following: Olympus AU5400 IZASA SA (Beckman Coulter); Synchron UniCel DXc600; Beckman 
Statistical analysis
Data were analyzed using the Statistical Analysis System software (Version 9.2, SAS Institute, Cary, NC). Characteristics of subjects from each of the four studies were summarized and compared as follows: categorical variables were analyzed using Pearson x 2 or Fisher exact tests. Continuous variables were tested using ANOVA for differences in means. Receiveroperating characteristic (ROC) curves were used to evaluate the diagnostic performance of the recommended HbA 1c cut points for IGT (HbA 1c $5.7%) and T1D (HbA 1c $6.5%). Optimal thresholds for HbA 1c versus OGTT were identified using three methodologies: 1) minimum distance to the point closest to (0,1) on the ROC curve (13); 2) Youden index, i.e., maximum of the sum of the sensitivity and specificity (14) ; and 3) positive likelihood ratio, where the ratio of the sensitivity to 1 2 specificity provides the greatest positive predictive value used to determine a cut point (15) . Prognostic accuracy was evaluated in each study with ROC analysis adjusted for censoring (the C-statistic). The area under the curve was calculated using the trapezoid rule.
RESULTSdThere were 587 subjects from DPT-1, 884 from TrialNet, 91 from TEDDY, and 420 from TRIGR. Based on OGTT, 135 were diagnosed with T1D in DPT-1, 87 in TrialNet, 33 in TEDDY, and 3 in TRIGR. Table 1 provides the total number of subjects ,21 years of age by study and those eligible to participate in this analysis. The majority of subjects (TrialNet 98%, DPT-1 87%, TEDDY 100%, and TRIGR 99%) for the primary analysis had an HbA 1c within 30 days of the paired OGTT. Of these, the vast majority (TrialNet 92%, DPT-1 70%, TEDDY 76%, and TRIGR 96%) had a HbA 1c -OGTT pair on the same day. Baseline characteristics and P values describing the significant differences across the groups are shown in Table 2 .
Sensitivity and specificity of HbA 1c cut points for IGT ($5.7%), T1D, and T1D-diagnosed asymptomatic hyperglycemia ($6.5%) compared with OGTT by study group are presented in Table 3 . Sensitivities and specificities were similar across the four studies for HbA 1c $6.5% (range 23.7-33.3 sensitivity and 97.6-99.8 specificity). Positive predictive values (PPVs) were variable; probability was 50-94% that a subject had T1D when HbA 1c was $6.5%. Similarly, the HbA 1c $6.5% threshold was not sensitive (27.3% TEDDY; 13.6% DPT-1), but it was specific (98.3% for both TEDDY and DPT-1) in asymptomatic hyperglycemic (no OGTT data) subjects diagnosed with T1D. TRIGR and TrialNet were not included in this analysis, since few asymptomatic subjects were diagnosed. PPVs were variable, ranging from 33 to 75% for the two studies. HbA 1c $5.7% sensitivities were low (8-42%), and specificities were variable (63-96%) in identifying IGT across the studies. PPVs were variable and poor with 9-60% likelihood of IGT if the HbA 1c was $5.7%. In addition, the diagnostic value of HbA 1c versus OGTT for both T1D and IGT was not statistically different by age across the four studies.
Given that few subjects were diagnosed with T1D by OGTT in TRIGR, the number of false positives (based on the eventual development of T1D with HbA 1c $6.5% versus the OGTT) was assessed to further evaluate the diagnostic utility of HbA 1c . There was only one false positive, and this subject did not develop T1D during the follow-up.
Lastly, ROC curves (Fig. 1A-C) comparing the sensitivity (true positive rate) versus 1 2 specificity (false positive rate) suggested lower thresholds than the current thresholds for T1D (Fig. 1A) , asymptomatic T1D (Fig. 1B) , and IGT (Fig. 1C) . ROC could only be performed for TEDDY and DPT-1 because of too few asymptomatic subjects diagnosed in TrialNet and TRIGR. We evaluated three statistical approaches to identify more optimal HbA 1c thresholds for the diagnosis of T1D, asymptomatic T1D, and IGT (shown in mean (SD) 12.5 (4.1) 11.2 (4.1) 2.5 (1.1) 5.2 (0.7) ,0.0001 *Missing race data: TEDDY, n = 31, and TRIGR, n = 1. care.diabetesjournals.org DIABETES CARE, VOLUME 35, SEPTEMBER 2012 Fig. 1A-C) . The alternative thresholds identified for this high-risk population were only slightly more sensitive, with a reduction in specificity.
CONCLUSIONSdThe alternative criterion proposed by the joint IEC to use HbA 1c $6.5% to diagnose T1D is premature given contradictory reports on its utility in pediatric and adolescent populations (16, 17 (4) reported that a 0.4% point increase in HbA 1c corresponded to a fivefold increase in T1D risk with modest increases starting as early as 5 years prior to diagnosis, followed by a sharp increase 6 months prior to diagnosis.
This analysis is not without limitations. Our primary limitation is that our population was all high risk, which accounts for 15-20% of all cases of T1D. Secondly, both the TEDDY and TRIGR studies did not conduct routine OGTTs; TRIGR only performed OGTTs on subjects $6 years of age, so it is possible that these subjects were further along in T1D progression and may have had higher HbA 1c levels as a result. The TRIGR study did not use a reference laboratory for processing HbA 1c and OGTT samples, and TEDDY used local laboratories for OGTT sample evaluations. Although these two studies used methods that adhere to a more practical manner of monitoring high-risk subjects, the TEDDY results were very similar to those found in both DPT-1 and TrialNet. The current study used the diagnostic HbA 1c in asymptomatic hyperglycemic subjects because two measures of HbA 1c were not uniformly collected in TEDDY at or postdiagnosis. A second HbA 1c is primarily used as a confirmation test, with the implication that it would reduce the number of false positives. However, our false-positive rate was very low (Table 3) . Given this, if a second HbA 1c failed to confirm diabetes then the sensitivity would actually be less than we have shown. Lastly, a 90-day window for the HbA 1c -OGTT pair was used to determine eligibility; however, the vast majority of the HbA 1c measures were conducted within 30 days of the OGTT. Although the HbA 1c is a 90-day moving average, it has been shown to be more heavily weighted toward the last 30 days; thus, we extended our analysis to assess the effect those few subjects who had an HbA 1c -OGTT pairing outside of the 30-day window had on our findings by only including those with a 30-day window and found there were no differences in sensitivity, specificity, or PPV.
The diagnostic performance of various diabetes indicators is in need of careful evaluation. Redefining a lower threshold for HbA 1c will be more optimal for diagnosing diabetes. Further understanding of the relationship between known markers of clinical disease (HbA 1c , FPG, random glucose, and OGTT) and T1D symptoms and complications with a focus on when to initiate treatment is needed. Until then, the OGTT, a sensitive indicator of diabetes and an early marker of impaired glucose homeostasis (18) , is the better diagnostic option for T1D.
